0 selections
0 selections

Alexion Pharmaceuticals Company History Timeline


Alexion Pharmaceuticals was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Cheshire, CT.“

The years since Alexion was established in 1992 have been extraordinary.

1992 – Alexion founded in New Haven, CT, USA.

Alexion Pharmaceuticals, established in 1992, is a renowned global biopharmaceuticals company best known for its Soliris drug used for the treatment of rare disorders such as atypical hemolytic uremic syndrome (aHUS). It has been in the forefront of research into autoimmune diseases.

Alexion Pharmaceuticals was founded by Leonard Bell in 1992 at Science Park in New Haven, Connecticut.

Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell.


1993 – C5 complement inhibitor development program commences.


1994 – First pilot manufacturing facility established in New Haven, CT, USA.


1996 – Initial public offering on NASDAQ under ticker symbol ALXN.


1998 – First in-human clinical trial of eculizumab begins,


In 2000, it purchased Proliferon Inc, a development stage biopharmaceutical firm based in California for us $41 mn in Alexion stock.

In 2000, Alexion purchased Proliferon Inc., a San Diego, California-based development-stage biopharmaceutical firm, for US$41 million in Alexion stock.


2002 – Pilot study with eculizumab commenced in Leeds, England in paroxysmal nocturnal hemoglobinuria (PNH).


2004 – Positive results from the pilot study with eculizumab in 11 patients with PNH published in the New England Journal of Medicine.


2005 – Alexion Europe SAS established in Paris, FranceSecond pivotal Phase 3 study of eculizumab in patients with PNH (SHEPHERD) begins.

The European office was started in 2005.


2006 – Biomanufacturing facility in Smithfield, RI, USA, acquired in anticipation of commercial-scale production of eculizumab.

2006 – Clinical data from the TRIUMPH PNH study published in the New England Journal of Medicine.


2007 – Soliris® approved by the FDA and European Medicines Agency as the first and only treatment for patients with PNH.


2008 – Soliris first as a treatment for patients with atypical hemolytic uremic syndrome (aHUS) in France and GermanySoliris awarded Prix Galien USA Award for Best Biotechnology Product with Broad Implications for Future Biomedical Research.


2009 – Soliris awarded the Prix Galien France Award for Drugs for Rare DiseasesAlexion’s Rhode Island manufacturing facility receives EU approval to supply Soliris.


In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany.


In April 2011, Alexion was added to the NASDAQ-100, a group composed of the 100 largest non-financial stocks traded on the NASDAQ; with a market value of USD 8.5 billion it replaced Genzyme Corporation.

In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia.

2011 – Alexion responds to a historic public health crisis in Germany and provides Soliris® without charge to hundreds of patients with life-threatening Shiga toxin E-coli-related hemolytic uremic syndrome (STEC-HUS).

In 2011, it acquired Enobia Pharma Corp, which is based in Montreal, Canada.


Leonard Bell was CEO from inception until March 2015 when he stepped down to make way for David Hallal.

In April 2015, Bell was replaced as CEO by David Hallal.

In May 2015, Alexion announced plans to purchase the Lexington firm Synageva BioPharma, a maker of rare disease treatments, in a $8.4 billion stock-and-cash deal.

Alexion moved back to New Haven following the completion of New Haven's Downtown Crossing project in December 2015.

Bell served as the company's CEO until 2015.


In December 2016, Alexion's board of directors announced new leadership.


In April 2018, Alexion announced the acquisition of Wilson Therapeutics for $855 million.


In October 2019, the business announced it would acquire Achillion Pharmaceuticals for $930 million, boosting its immune system disease pipeline.

Elliott argues that Alexion management's actions, including the o.m. recent move to acquire Portola for about $1.4 billion, are leading in the "wrong direction." In December 2019, Alexion's board unanimously rejected a recommendation by Elliott to immediately launch a proactive sale.


In May 2020, Alexion announced an agreement to acquire Portola Pharmaceuticals for $18 per share using cash.

Company Founded
Boston, MA
Company Headquarter
Abel Fernandez,Leonard Bell,Stephen Squinto
Company Founders
Get Updates for Jobs and News

Alexion Pharmaceuticals Jobs Nearby

Alexion Pharmaceuticals Jobs

Alexion Pharmaceuticals Similar Companies

Company NameFounded DateRevenueEmployee SizeJob Openings
Vertex Pharmaceuticals1989$6.2B3,000298
Regeneron Pharmaceuticals1988$8.5B9,123888
Johnson & Johnson1886$82.6B134,5003,137
Gilead Sciences1987$24.7B11,800851
Baxter International1931$11.7B48,0004,668
Find Jobs from Similar Companies
Personalize your job search. Where would you like to work?
0 selections

Alexion Pharmaceuticals Similar Companies Jobs

Zippia gives an in-depth look into the details of Alexion Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Alexion Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Alexion Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Alexion Pharmaceuticals. The data presented on this page does not represent the view of Alexion Pharmaceuticals and its employees or that of Zippia.

Alexion Pharmaceuticals may also be known as or be related to Alexion, Alexion Pharmaceuticals, Alexion Pharmaceuticals Inc and Alexion Pharmaceuticals, Inc.